Trial reportPloS one2020
A multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization.
Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Efficacy and safety of nebulized inhalation vs. intramuscular delivery of interferon α1b injection for paediatric patients with viral respiratory diseases: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- What we know so far about Coronavirus Disease 2019 in children: A meta-analysis of 551 laboratory-confirmed cases.Pediatric pulmonology · 2020Pooled it
- Differential antiviral effects and immune responses in nasal and airway organoid during RSV infection: implications for interferon therapy.Frontiers in immunology · 2026Article
- First use of nitazoxanide in Kelleni's protocol for managing severe bronchiolitis in a 9-month-old infant: A case report and review of literature.World journal of clinical cases · 2025Article
- ARCN1 suppresses innate immune responses against respiratory syncytial virus by promoting STUB1-mediated IKKε degradation.PLoS pathogens · 2025Article
- The protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with H1N1 influenza A virus.Archives of microbiology · 2025Article
- Guideline for the diagnosis, treatment, and prevention of respiratory syncytial virus infection in children in China.Pediatric investigation · 2025Article
- Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection.Viruses · 2025Review
- Safety evaluation and toxicokinetics of repeated inhalation exposure to pegylated interferon α-2b.Frontiers in pharmacology · 2025Article
- Dialogue pathways and narrative analysis in health communication within the social media environment: an empirical study based on user behavior-a case study of China.Frontiers in public health · 2025Article
- Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.International journal of molecular sciences · 2022Review
- Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro.Virologica Sinica · 2022Article
- Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies.PLOS global public health · 2022Article
- Safety and Effectiveness of Inhaling Different Dosage Recombinant Human InterferonEvidence-based complementary and alternative medicine : eCAM · 2022Article
- COVID-19 challenges and its therapeutics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Enhanced delivery efficiency and sustained release of biopharmaceuticals by complexation-based gel encapsulated coated microneedles: rhIFNα-1b example.Asian journal of pharmaceutical sciences · 2021Article
- Function and Modulation of Type I Interferons during Respiratory Syncytial Virus Infection.Vaccines · 2020Review
- Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study.Frontiers in medicine · 2020Article
- Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response.Therapeutic advances in infectious diseaseArticle
- Article
Corrections and comments
- Erratum issued
Authors and funding
45 authors at 18 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe respiratory syncytial virus (RSV) is the main cause of bronchiolitis in infants and interferon (IFN) α is a commercial antiviral drug. The nebulization of IFN α1b could be a viable treatment method. In this study, the therapeutic effects and safety of IFN α1b delivery via nebulization in infant bronchiolitis were investigated in this multi-center prospective study. METHODS AND
findingsBronchiolitis patients admitted to 22 hospitals who met the inclusion criteria were enrolled and randomly allocated to four groups: control, IFN Intramuscular Injection, IFN Nebulization 1 (1 μg/kg), and IFN Nebulization 2 (2 μg/kg) groups. All patients were observed for 7 days. The therapeutic effects and safety of different IFN delivery doses and delivery modes were evaluated. Coughing severity change, as scored by the researchers and parents, between days 1 and 3 was significantly different between the IFN Nebulization 2 and control groups. Lowell wheezing score change between days 3 and 5 was significantly different between IFN Nebulization 1 and control groups. There were no significant differences among the four groups regarding the number of consecutive days with fever, three-concave sign, fatigue and sleepiness, and loss of appetite. There were no cases of severe complications, no recurrence of fever, and no regression of mental status.
conclusionsIFN-α1b could more effectively alleviate coughing and wheezing in bronchiolitis. IFN-α1b nebulization had significant advantages in shortening the duration of wheezing and alleviating coughing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.